This case highlights the need for clinical vigilance regarding rare but severe paclitaxel-induced pulmonary hypersensitivity and vascular inflammation when using paclitaxel-eluting stents for peripheral arterial disease.
Raises caution for paclitaxel dose limits in peripheral stents; single case leaves open causality and population risk.
We report a case of interstitial pneumonitis after paclitaxel-eluting stent implantation for peripheral arterial disease in a 74-year-old man. Five weeks after the procedure, the patient developed dyspnea and bilateral ground-glass opacities, with a paclitaxel dose (1169 μg) exceeding the recommended limit (1034 μg). Hypersensitivity to paclitaxel likely caused interstitial pneumonitis, confirmed by elevated Krebs von den Lungen-6 levels and exclusion of other etiologies. Corticosteroid therapy improved symptoms. Clinicians should monitor for rare but serious paclitaxel-induced pulmonary hypersensitivity in patients with peripheral arterial disease.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: